Repligen Corporation (RGEN)

Market Cap	9.63B
Revenue (ttm)	707.89M
Net Income (ttm)	1.74M
Shares Out	56.29M
EPS (ttm)	0.03
PE Ratio	5,539.04
Forward PE	88.67
Dividend	n/a
Ex-Dividend Date	n/a

Volume	388,096
Open	174.01
Previous Close	171.18
Day's Range	168.70 - 174.01
52-Week Range	102.97 - 182.52
Beta	1.13
Analysts	Buy
Price Target	170.90 (-0.02%)
Earnings Date	Oct 28, 2025

About RGEN

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1981
• Employees: 1,778
• Stock Exchange: NASDAQ
• Ticker Symbol: RGEN
• Website: https://www.repligen.com

Analyst Summary

According to 10 analysts, the average rating for RGEN stock is "Buy." The 12-month stock price target is $170.9, which is a decrease of -0.02% from the latest price.

Price Target

$170.9

(-0.02% downside)

Analyst Consensus: Buy